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appreciable reductions in newborn 
mortality in low-income and middle-
income countries. We said that 
two recent trials9,10 did not provide 
evidence to alter current WHO 
guidelines,7 which recommend it for 
infants born at home in environments 
with neonatal mortality rates of more 
than 30 per 1000 livebirths. We stand 
by this.
DO does not work with but has been a co-author of 
six publications in the past 5 years with 
Robert Black, a named author of the paper from 
Tanzania. The publications were produced by large 
working groups and DO and TC both either 
contributed data from their research programmes 
or were members of a distributed expert group. 
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Authors’ reply
Stephen Hodgins says that cord 
application of chlorhexidine protects 
infants against omphalitis equally after 
birth at home or in hospital, and that 
we were incorrect to say that it was not 
eﬀ ective for infants born in hospital.
The first point is well taken. The 
2015 Cochrane review1 suggests that 
risk ratios (RR) for omphalitis were 
similar in hospital (RR 0·48, 95% CI 
0·28–0·84) and community trials 
(0·48, 0·40–0·57). The 2013 Cochrane 
review2 included nine relevant hospital 
studies of chlorhexidine application. 
For omphalitis, one study3 suggested 
a beneﬁ t versus dry cord care (0·28, 
0·06–1·35); another study4 found 
no benefit versus alcohol (2·77, 
0·12–66·49), and another5 found no 
beneﬁ t over hydrophobic gauze (1·36, 
0·55–3·36). Imdad and colleagues2 
suggested that, “…compared with 
dry cord care, no antiseptic was 
convincingly advantageous to reduce 
the incidence of omphalitis.”
The 2015 Cochrane review addressed 
cord cleansing, more extensive skin 
cleansing, and maternal vaginal 
washing.1 One trial6 in India suggested 
that, compared with dry cord care, 
chlorhexidine cord cleansing was 
associated with a non-significant 
reduction in mortality (RR 0·11, 95% CI 
0·01–2·04). This and a trial in Germany3 
suggested that chlorhexidine cord 
cleansing was associated with lower 
risk of omphalitis. The review1 made 
no recommendation for hospital 
births, saying that the “…quality of 
evidence for the eﬀ ects on infection 
are moderate for cord application”.
The trial in Germany3 compared 
healthy term infants (>2500 g) in 
two neonatal nurseries treated with 
chlorhexidine 1% powder (337 infants) 
or dry cord care (332 infants). Sample 
size was based on the primary 
outcome of cord separation time but 
recruitment shortfalls necessitated 
respecification of the detectable 
difference. Hodgins summarises 
adverse events. Omphalitis was 
identified in two infants in the 
chlorhexidine group and seven in 
the dry cord care group. All cases but 
one were described as mild. The 2015 
Cochrane review1 downgraded its 
classiﬁ cation because of “…serious risk 
of selection bias, performance bias and 
detection bias”.
The trial in India6 compared 
application of chlorhexidine 2·5% 
solution to the cords of 70 infants 
with dry cord care for 70 infants, all 
of them older than 32 weeks and 
weighing more than 1499 g and 
judged on enrolment as likely to spend 
at least 5 days in a neonatal intensive 
care unit. The sample size was again 
based on the primary outcome of cord 
separation time. Culture-confirmed 
sepsis was lower in the chlorhexidine 
group (RR 0·13, 95% CI 0·02–0·40). The 
2015 Cochrane review1 downgraded 
its classiﬁ cation of bias risk because 
of imprecision. Together, these trials 
included 809 infants.
Hodgins’ second point interprets a 
statement we made, quoting the WHO 
recommendation,7 and saying that the 
Cochrane reviews,1,2 a meta-analysis,8 
and the two trials in The Lancet Global 
Health9,10 had not supported an eﬀ ect 
after hospital births. Our Comment11 
begins with, and is permeated by, 
an emphasis on newborn mortality. 
As Hodgins says, community-based 
trials8–10 suggest that the effect on 
neonatal mortality was similar—
even when non-significant—when 
infants were born in hospital. We do 
not take issue with this. Indeed, we 
acknowledge the complete statement 
by Sazawal and colleagues:10 “The 
ﬁ ndings in our study suggest that use 
of chlorhexidine for the reduction of 
omphalitis is justiﬁ ed, but in an African 
setting there is insuﬃ  cient evidence to 
promote this intervention to reduce 
neonatal mortality.”
The emphasis of our Comment 
was on whether cord application 
of chlorhexidine might achieve 
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